References
- Luisetti M, Miravitlles M, Stockley R A. Alpha1‐antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001. Eur Respir J 2002; 20(4)1050–1056, [PUBMED], [INFOTRIEVE]
- Laurell C B, Eriksson S. The electrophoretic a1‐globulin pattern of serum in a1‐antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 133–140
- Carrell R W, Lomas D A. Conformational disease. Lancet 1997; 350(9071)134–138, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lomas D A, Carrell R W. Serpinopathies and the conformational dementias. Nat Rev, Genet 2002; 3(10)759–768, [CROSSREF]
- Carrell R W, Lomas D A. Alpha1‐antitrypsin deficiency—a model for conformational diseases. N Engl J Med 2002; 346(1)45–53, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Davis R L, Shrimpton A E, Carrell R W, Lomas D A, Gerhard L, Baumann B, Lawrence D A, Yepes M, Kim T S, Ghetti B, Piccardo P, Takao M, Lacbawan F, Muenke M, Sifers R N, Bradshaw C B, Kent P F, Collins G H, Larocca D, Holohan P D. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002; 359(9325)2242–2247, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mahadeva R, Dafforn T R, Carrell R W, Lomas D A. 6‐mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)‐antitrypsin‐related cirrhosis. J Biol Chem 2002; 277(9)6771–6774, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rodriguez‐Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117(5 suppl 2)398S–401S, [CROSSREF]
- Anthonisen N R, Manfreda J, Warren C P, Hershfield E S, Harding G K, Nelson N A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106(2)196–204, [PUBMED], [INFOTRIEVE]
- Dowson L J, Guest P J, Stockley R A. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)‐antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001; 164(10 Pt. 1)1805–1809, [PUBMED], [INFOTRIEVE], [CSA]
- Hill A T, Campbell E J, Bayley D L, Hill S L, Stockley R A. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)‐antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999; 160(6)1968–1975, [PUBMED], [INFOTRIEVE], [CSA]
- Dowson L J, Guest P J, Stockley R A. The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha(1)‐antitrypsin deficiency (PiZ). Chest 2002; 122(4)1247–1255, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118(5)1480–1485, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Dirksen A, Dijkman J H, Madsen F, Stoel B, Hutchison D C, Ulrik C S, Skovgaard L T, Kok‐Jensen A, Rudolphus A, Seersholm N, Vrooman H A, Reiber J H, Hansen N C, Heckscher T, Viskum K, Stolk J. A randomized clinical trial of alpha(1)‐antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160(5 Pt. 1)1468–1472, [PUBMED], [INFOTRIEVE], [CSA]
- Koulouris N G. Negative expiratory pressure: a new tool. Monaldi Arch Chest Dis 2002; 57(1)69–75, [PUBMED], [INFOTRIEVE], [CSA]
- Brantly M L, Wittes J T, Vogelmeier C F, Hubbard R C, Fells G A, Crystal R G. Use of a highly purified alpha 1‐antitrypsin standard to establish ranges for the common normal and deficient alpha 1‐antitrypsin phenotypes. Chest 1991; 100(3)703–708, [PUBMED], [INFOTRIEVE]
- Dahl M, Nordestgaard B G, Lange P, Vestbo J, Tybjaerg‐Hansen A. Molecular diagnosis of intermediate and severe alpha(1)‐antitrypsin deficiency: MZ individuals with chronic obstructive pulmonary disease may have lower lung function than MM individuals. Clin Chem 2001; 47(1)56–62, [PUBMED], [INFOTRIEVE], [CSA]
- Dahl M, Tybjaerg‐Hansen A, Lange P, Vestbo J, Nordestgaard B G. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1‐antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med 2002; 136(4)270–279
- de Serres F J. Worldwide racial and ethnic distribution of alpha1‐antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122(5)1818–1829, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Seersholm N, Kok‐Jensen A. Intermediate alpha 1‐antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema?. Respir Med 1998; 92(2)241–245, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Turino G M, Barker A F, Brantly M L, Cohen A B, Connelly R P, Crystal R G, Eden E, Schluchter M D, Stoller J K. Clinical features of individuals with PI*SZ phenotype of alpha 1‐antitrypsin deficiency. Alpha 1‐Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996; 154(6 Pt. 1)1718–1725, [PUBMED], [INFOTRIEVE], [CSA]
- Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood D E. A randomized trial comparing lung‐volume‐reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348(21)2059–2073, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mahadeva R, Shapiro S D. Chronic obstructive pulmonary disease * 3: experimental animal models of pulmonary emphysema. Thorax 2002; 57(10)908–914, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Morris D G, Huang X, Kaminski N, Wang Y, Shapiro S D, Dolganov G, Glick A, Sheppard D. Loss of integrin alpha(v)beta6‐mediated TGF‐beta activation causes Mmp12‐dependent emphysema. Nature 2003; 422(6928)169–173, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Churg A, Wang R D, Tai H, Wang X, Xie C, Dai J, Shapiro S D, Wright J L. Macrophage metalloelastase mediates acute cigarette smoke‐induced inflammation via tumor necrosis factor‐alpha release. Am J Respir Crit Care Med 2003; 167(8)1083–1089, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Roberts A B. Medicine: smoke signals for lung disease. Nature 2003; 422(6928)130–131, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Reid P T, Sallenave J M. Cytokines in the pathogenesis of chronic obstructive pulmonary disease. Curr Pharm Des 2003; 9(1)25–38, [PUBMED], [INFOTRIEVE], [CSA]
- Fujita M, Shannon J M, Irvin C G, Fagan K A, Cool C, Augustin A, Mason R J. Overexpression of tumor necrosis factor‐alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol, Lung Cell Mol Physiol 2001; 280(1)L39–L49, [CSA]
- Lucey E C, Keane J, Kuang P P, Snider G L, Goldstein R H. Severity of elastase‐induced emphysema is decreased in tumor necrosis factor‐alpha and interleukin‐1beta receptor‐deficient mice. Lab Invest 2002; 82(1)79–85, [PUBMED], [INFOTRIEVE], [CSA]
- Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159(1)158–164, [PUBMED], [INFOTRIEVE], [CSA]
- Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M, Oswald‐Mammosser M. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164(2)219–224, [PUBMED], [INFOTRIEVE], [CSA]
- Santos S, Peinado V I, Ramirez J, Melgosa T, Roca J, Rodriguez‐Roisin R, Barbera J A. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19(4)632–638, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Malone M, Mieli‐Vergani G, Mowat A P, Portmann B. The fetal liver in PiZZ alpha‐1‐antitrypsin deficiency: a report of five cases. Pediatr Pathol 1989; 9(6)623–631, [PUBMED], [INFOTRIEVE]
- Pittschieler K, Massi G. Liver involvement in infants with PiSZ phenotype of alpha 1‐antitrypsin deficiency. J Pediatr Gastroenterol Nutr 1992; 15(3)315–318, [PUBMED], [INFOTRIEVE]
- Sveger T, Eriksson S. The liver in adolescents with alpha 1‐antitrypsin deficiency. Hepatology 1995; 22(2)514–517, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mahadeva R, Chang W S, Dafforn T R, Oakley D J, Foreman R C, Calvin J, Wight D G, Lomas D A. Heteropolymerization of S, I, and Z alpha1‐antitrypsin and liver cirrhosis. J Clin Invest 1999; 103(7)999–1006, [PUBMED], [INFOTRIEVE], [CSA]
- Whitehouse D B, Lovegrove J U, Mieli‐Vergani G, Mowat A P, Hopkinson D A. ‘SZ like’ alpha 1‐antitrypsin phenotypes in PI ZZ children with liver disease. Ann Hum Genet 1994; 58(Pt. 1)11–17, [PUBMED], [INFOTRIEVE]
- Pittschieler K. Rare alpha‐1‐antitrypsin phenotypes and liver‐test abnormalities during infancy. Acta Paediatr 2001; 90(4)406–408, [PUBMED], [INFOTRIEVE]
- Seixas S, Lopes A I, Rocha J, Silva L, Salgueiro C, Salazar‐de‐Sousa J, Batista A. Association between the defective Pro369Ser mutation and in vivo intrahepatic 1‐antitrypsin accumulation. J Med Genet 2001; 38(7)472–474, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Canva V, Piotte S, Aubert J P, Porchet N, Lecomte‐Houcke M, Huet G, Zenjari T, Roumilhac D, Pruvot F R, Degand P, Paris J C, Balduyck M. Heterozygous M3Mmalton alpha1‐antitrypsin deficiency associated with end‐stage liver disease: case report and review. Clin Chem 2001; 47(8)1490–1496, [PUBMED], [INFOTRIEVE], [CSA]
- Lin L, Schmidt B, Teckman J, Perlmutter D H. A naturally occurring nonpolymerogenic mutant of alpha 1‐antitrypsin characterized by prolonged retention in the endoplasmic reticulum. J Biol Chem 2001; 276(36)33893–33898, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cabral C M, Liu Y, Moremen K W, Sifers R N. Organizational diversity among distinct glycoprotein endoplasmic reticulum‐associated degradation programs. Mol Biol Cell 2002; 13(8)2639–2650, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Teckman J H, Burrows J, Hidvegi T, Schmidt B, Hale P D, Perlmutter D H. The proteasome participates in degradation of mutant alpha 1‐antitrypsin Z in the endoplasmic reticulum of hepatoma‐derived hepatocytes. J Biol Chem 2001; 276(48)44865–44872, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Perlmutter D H. Liver injury in alpha1‐antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest 2002; 110(11)1579–1583, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Teckman J H, An J K, Loethen S, Perlmutter D H. Fasting in alpha1‐antitrypsin deficient liver: constitutive activation of autophagy. Am J Physiol: Gastrointest Liver Physiol 2002; 283(5)G1156–G1165, [CSA]
- World Health Organization. Alpha 1‐antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 1997; 75(5)397–415, [CSA]
- Fischer H P, Ortiz‐Pallardo M E, Ko Y, Esch C, Zhou H. Chronic liver disease in heterozygous alpha1‐antitrypsin deficiency PiZ. J Hepatol 2000; 33(6)883–892, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Carlson J, Eriksson S. Chronic ‘cryptogenic’ liver disease and malignant hepatoma in intermediate alpha 1‐antitrypsin deficiency identified by a Pi Z‐specific monoclonal antibody. Scand J Gastroenterol 1985; 20(7)835–842, [PUBMED], [INFOTRIEVE]
- Elzouki A N, Segelmark M, Wieslander J, Eriksson S. Strong link between the alpha 1‐antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med 1994; 236(5)543–548, [PUBMED], [INFOTRIEVE]
- Janciauskiene S, Dominaitiene R, Sternby N H, Piitulainen E, Eriksson S. Detection of circulating and endothelial cell polymers of Z and wild type alpha 1‐antitrypsin by a monoclonal antibody. J Biol Chem 2002; 277(29)26540–26546, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stoller J K, Brantly M, Fleming L E, Bean J A, Walsh J. Formation and current results of a patient‐organized registry for alpha(1)‐antitrypsin deficiency. Chest 2000; 118(3)843–848, [PUBMED], [INFOTRIEVE]
- McElvaney N G, Stoller J K, Buist A S, Prakash U B, Brantly M L, Schluchter M D, Crystal R D. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1‐antitrypsin deficiency. Alpha 1‐Antitrypsin Deficiency Registry Study Group. Chest 1997; 111(2)394–403, [PUBMED], [INFOTRIEVE]
- National Heart Lung and Blood Institute. Survival and FEV1 decline in individuals with severe deficiency of alpha1‐antitrypsin. The Alpha‐1‐Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158(1)49–59, [CSA]
- Gomez F P, Rodriguez‐Roisin R. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease. Curr Opin Pulm Med 2002; 8(2)81–86, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sveger T. Liver disease in alpha1‐antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294(24)1316–1321, [PUBMED], [INFOTRIEVE]
- Sveger T, Ohlsson K, Piitulainen E. Adolescents with alpha1‐antitrypsin deficiency have high alpha2‐macroglobulin and low neutrophil lipocalin and elastase levels in plasma. Pediatr Res 1998; 44(6)939–941, [PUBMED], [INFOTRIEVE], [CSA]
- Piitulainen E, Sveger T. Respiratory symptoms and lung function in young adults with severe alpha(1)‐antitrypsin deficiency (PiZZ). Thorax 2002; 57(8)705–708, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok‐Jensen A, Konietzko N. Does alpha1‐antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1‐antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) Alpha1‐AT Study Group. Eur Respir J 1997; 10(10)2260–2263, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gottlieb D J, Luisetti M, Stone P J, Allegra L, Cantey‐Kiser J M, Grassi C, Snider G L. Short‐term supplementation therapy does not affect elastin degradation in severe alpha(1)‐antitrypsin deficiency. The American–Italian AATD Study Group. Am J Respir Crit Care Med 2000; 162(6)2069–2072, [PUBMED], [INFOTRIEVE], [CSA]
- Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow‐up of patients with alpha(1)‐protease inhibitor deficiency before and during therapy with IV alpha(1)‐protease inhibitor. Chest 2001; 119(3)737–744, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stockley R A, Bayley D L, Unsal I, Dowson L J. The effect of augmentation therapy on bronchial inflammation in alpha1‐antitrypsin deficiency. Am J Respir Crit Care Med 2002; 165(11)1494–1498, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, Brantly M, Muzyczka N, Byrne B J, Atkinson M, Flotte T R. Sustained secretion of human alpha‐1‐antitrypsin from murine muscle transduced with adeno‐associated virus vectors. Proc Natl Acad Sci U S A 1998; 95(24)14384–14388, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Song S, Scott‐Jorgensen M, Wang J, Poirier A, Crawford J, Campbell‐Thompson M, Flotte T R. Intramuscular administration of recombinant adeno‐associated virus 2 alpha‐1 antitrypsin (rAAV‐SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Molec Ther 2002; 6(3)329–335, [CROSSREF], [CSA]
- Flotte T R. Recombinant adeno‐associated virus gene therapy for cystic fibrosis and alpha(1)‐antitrypsin deficiency. Chest 2002; 121(3 Suppl.)98S–102S, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stoll S M, Sclimenti C R, Baba E J, Meuse L, Kay M A, Calos M P. Epstein‐Barr virus/human vector provides high‐level, long‐term expression of alpha1‐antitrypsin in mice. Molec Ther 2001; 4(2)122–129, [CROSSREF], [CSA]
- Metz R, DiCola M, Kurihara T, Bailey A, Frank B, Roecklein B, Blaese M. Mode of action of RNA/DNA oligonucleotides: progress in the development of gene repair as a therapy for alpha(1)‐antitrypsin deficiency. Chest 2002; 121(3 suppl)91S–97S, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Dasi F, Benet M, Crespo J, Crespo A, Alino S F. Asialofetuin liposome‐mediated human alpha1‐antitrypsin gene transfer in vivo results in stationary long‐term gene expression. J Mol Med 2001; 79(4)205–212, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wege H, Le H T, Chui M S, Liu L, Wu J, Giri R, Malhi H, Sappal B S, Kumaran V, Gupta S, Zern M A. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003; 124(2)432–444, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cantor J O, Cerreta J M, Keller S, Turino G M. Modulation of airspace enlargement in elastase‐induced emphysema by intratracheal instillment of hyaluronidase and hyaluronic acid. Exp Lung Res 1995; 21(3)423–436, [PUBMED], [INFOTRIEVE], [CSA]
- Massaro G D, Massaro D. Retinoic acid treatment abrogates elastase‐induced pulmonary emphysema in rats. Nat Med 1997; 3(6)675–677, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Burrows J A, Willis L K, Perlmutter D H. Chemical chaperones mediate increased secretion of mutant alpha 1‐antitrypsin (alpha 1‐AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1‐AT deficiency. Proc Natl Acad Sci U S A 2000; 97(4)1796–1801, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]